Ye Rim Kim

Ye Rim Kim

Auto-generated profile, based on publicly available information

Ye Rim Kim

Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2024 in Journal of Hepatocellular Carcinoma
Verified
Journal Article
Open access
PDF file
YKYe Rim Kim
Ye Rim Kim
SCSung Won Chung
Sung Won Chung
MKMin-Ju Kim
Min-Ju Kim
WCWon-Mook Choi
Won-Mook Choi
JCJonggi Choi
Jonggi Choi
JSJu Hyun Shim
Ju Hyun Shim
Introduction: We aimed to evaluate the generalizability of retrospective single-center cohort studies on prognosis of hepatocellular carcinoma (HCC) by comparing overall survival (OS) after various treatments between a nationwide multicenter cohort and a single-center cohort of HCC patients. Methods: Patients newly diagnosed with HCC between January 2008 and December 2018 were analyzed using data from the Korean Primary Liver Cancer Registry (multicenter cohort, n=16,443), and the Asan Medical Center HCC registry (single-center cohort, n=15,655). The primary outcome, OS after initial treatment, was compared between the two cohorts for both the entire population and for subcohorts with Child-Pugh A liver function (n=2797 and n=5151, respectively) treated according to the Barcelona-Clinic-Liver-Cancer (BCLC) strategy, using Log rank test and Cox proportional hazard models. Results: Patients of BCLC stages 0 and A (59.3% vs 35.2%) and patients who received curative treatment (42.1% vs 32.1%) were more frequently observed in the single-center cohort (Ps< 0.001). Multivariable analysis revealed significant differences between the two cohorts in OS according to type of treatment: the multicenter cohort was associated with higher risk of mortality among patients who received curative (adjusted hazard ratio [95% confidence interval], 1.48 [1.39– 1.59]) and non-curative (1.22 [1.17– 1.27]) treatments, whereas the risk was lower in patients treated with systemic therapy (0.83 [0.74– 0.92]) and best supportive care (0.85 [0.79– 0.91]). Subcohort analysis also demonstrated significantly different OS between the two cohorts, with a higher risk of mortality in multicenter cohort patients who received chemoembolization (1.72 [1.48– 2.00]) and ablation (1.44 [1.08– 1.92]). Conclusion: Comparisons of single-center and multicenter cohorts of HCC patients revealed significant differences in OS according to treatment modality after adjustment for prognostic variables. Therefore, the results of retrospective single-center cohort studies of HCC treatments may not be generalizable to real-world practice.

21 October 2025 in Gut and Liver
Verified
Journal Article
Open access
PDF file
JYJiwon Yang
Jiwon Yang
YKYe Rim Kim
Ye Rim Kim
SNSeong Kyun Na
Seong Kyun Na
SKSeon-Ok Kim
Seon-Ok Kim
JAJihyun An
Jihyun An
JSJu Hyun Shim
Ju Hyun Shim
Jiwon Yang, Ye Rim Kim, Seong Kyun Na, Seonok Kim, Jihyun An, Ju Hyun Shim. Gut and Liver -0001;0:. https://doi.org/10.5009/gnl250275